BLK inhibition will target the CSC population, while chemotherapy eliminates bulk tumor cells, creating a two-pronged therapeutic strategy that accounts for DSRCT heterogeneity and can hopefully improve patient survival. The gene discussed is BLK; the disease is neoplasm.